Lv5
1010 积分 2025-02-27 加入
Current situation of zalutumumab
3个月前
已完结
ERBB receptors and cancer: the complexity of targeted inhibitors
6个月前
已完结
Emerging importance of HER3 in tumorigenesis and cancer therapy
6个月前
已完结
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China
7个月前
已完结
Unveiling the molecular and immunological drivers of antibody–drug conjugates in cancer treatment
8个月前
已完结
Raludotatug deruxtecan monotherapy among patients with previously treated ovarian cancer: Subgroup analysis of a first-in-human phase I study
8个月前
已完结
Major Strides in HER2 Blockade for Metastatic Breast Cancer
8个月前
已完结
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China
8个月前
已完结
Thirty Years of HER3: From Basic Biology to Therapeutic Interventions
8个月前
已完结
皖公网安备34019202002308
